The political and policy focus on drug prices continues in 2022 in key markets across the globe. In particular, in the U.S., UK, and EU, policymakers continue work on alternatives to the current reimbursement and procurement regimes, potentially affecting research and development, including in areas of unmet need and of patient-friendly formulations of medications. In China, stakeholders should be aware that following a recent pricing negotiation with the central government, the average price cut for nearly 70 products for the next two years is approximately 60%. This update discusses material legislative, policy, and litigation developments affecting drug pricing across the globe. Continue reading

See all Member News